-
Sector Analysis
Prostate Cancer Epidemiology Analysis and Forecast to 2033
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with...
-
Product Insights
Metastatic Prostate Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic prostate cancer occurs when cancerous cells from the prostate gland spread via the bloodstream or lymphatic system to distant sites, especially the bones (such as the spine, pelvis, or hips), lymph nodes, liver, lungs, and other organs. It's considered an advanced stage of prostate cancer and can present challenges in treatment and management. Metastatic prostate cancer can cause various symptoms...
-
Product Insights
Penile Cancer - Drugs In Development, 2024
Empower your strategies with our Penile Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Penile cancer is a rare malignancy that develops on the skin or tissues of the penis. It occurs when normal cells in the penis undergo genetic mutations, leading to uncontrolled growth and the formation of a cancerous tumor. Early stages of penile cancer might not cause noticeable symptoms. As the disease progresses, signs and symptoms may include changes in skin color or...
-
Product Insights
Hormone-Sensitive Prostate Cancer - Drugs In Development, 2024
Empower your strategies with our Hormone-Sensitive Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they...
-
Product Insights
Testicular Cancer - Drugs In Development, 2024
Empower your strategies with our Testicular Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Testicular cancer stands out as a prevalent malignancy affecting men in the age group of 15 to 45 years. Its etiology is complex, involving a combination of genetic and environmental factors. Advancements in understanding the epidemiology, pathophysiology, and diagnostic approaches have paved the way for sophisticated management strategies. Notably, the prognosis for testicular cancer has significantly improved, boasting cure rates reaching up...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.